Investment
Features
FeesSafety
Academy
More
Pluang+

abrdn Asia-Pacific Income Fund rated Hold due to risks from high leverage and unsustainable yield.

Market News
14 Aug 2026
Seeking Alpha
View Source
Bearish
pluang ai news

The abrdn Asia-Pacific Income Fund (FAX) is rated as a Hold because its negatives outweigh positives. The fund's high leverage, close to regulatory limits, risks forced deleveraging and net asset value erosion if markets decline. Although it offers a 13.61% yield, this is not supported by net investment income, increasing the chance of future distribution cuts or continued erosion. The fund provides exposure to investment-grade Asia-Pacific government-related debt but lacks strong forward return potential without a significant emerging market rally.

More News

OptimumBank's price target raised to $11 amid strong financial growth and profitability.

OptimumBank's price target raised to $11 amid strong financial growth and profitability.

Industrial Alliance Securities raised OptimumBank Holdings' price target from $7.00 to $11.00, signaling a 15.24% potential upside. The bank shows strong financial health with a 2.04% ROAA, 20.34% ROAE, and a 4.57% net interest margin. Its loans grew...

Analyst Insights
Bullish
1 hour ago
Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...

Analyst Insights
Bearish
2 hours ago
Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...

Market News
Bullish
2 hours ago
Life360 director Morin Brit sells 15,582 shares for $1 million

Life360 director Morin Brit sells 15,582 shares for $1 million

Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...

Market News
Bearish
2 hours ago
AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.

AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.

AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App